Targeting FoxO1 with AS1842856 Suppresses Adipogenesis

References

• Cheng Z, Almeida FA. Mitochondrial alteration in type 2 diabetes and obesity: an epigenetic link. Cell Cycle 2014; 13:890-7; PMID:24552811; http://dx.doi.org/10.4161/cc.28189
   PubMed Web of Science ®Google Scholar
• Cheng Z, Schmelz EM, Liu D, Hulver MW. Targeting mitochondrial alterations to prevent type 2 diabetes-Evidence from studies of dietary redox-active compounds. Mol Nutr Food Res 2014; 58(8):1739-49; PMID:24668725; http://dx.doi.org/10.1002/mnfr.201300747
   PubMed Web of Science ®Google Scholar
• Wang QA, Tao C, Gupta RK, Scherer PE. Tracking adipogenesis during white adipose tissue development, expansion and regeneration. Nat Med 2013; 19:1338-44; PMID:23995282; http://dx.doi.org/10.1038/nm.3324
   PubMed Web of Science ®Google Scholar
• Niswender K. Diabetes and obesity: therapeutic targeting and risk reduction - a complex interplay. Diabetes Obes Metab 2010; 12:267-87; PMID:20380648; http://dx.doi.org/10.1111/j.1463-1326.2009.01175.x
   PubMed Web of Science ®Google Scholar
• Cheng Z, White MF. Targeting Forkhead box O1 from the concept to metabolic diseases: lessons from mouse models. Antioxidants & Redox Signaling 2011; 14:649-61; PMID:20615072; http://dx.doi.org/10.1089/ars.2010.3370
   PubMed Web of Science ®Google Scholar
• De Pauw A, Tejerina S, Raes M, Keijer J, Arnould T. Mitochondrial (dys)function in adipocyte (de)differentiation and systemic metabolic alterations. Am J Pathol 2009; 175:927-39; PMID:19700756; http://dx.doi.org/10.2353/ajpath.2009.081155
   PubMed Web of Science ®Google Scholar
• Kusminski CM, Scherer PE. Mitochondrial dysfunction in white adipose tissue. Trend endocrinol Metab: TEM 2012; 23:435-43; http://dx.doi.org/10.1016/j.tem.2012.06.004
   PubMed Web of Science ®Google Scholar
• Gesta S, Tseng YH, Kahn CR. Developmental origin of fat: tracking obesity to its source. Cell 2007; 131:242-56; PMID:17956727; http://dx.doi.org/10.1016/j.cell.2007.10.004
   PubMed Web of Science ®Google Scholar
• Farmer SR. Transcriptional control of adipocyte formation. Cell Metab 2006; 4:263-73; PMID:17011499; http://dx.doi.org/10.1016/j.cmet.2006.07.001
   PubMed Web of Science ®Google Scholar
• Rosen ED, Spiegelman BM. What we talk about when we talk about fat. Cell 2014; 156:20-44; PMID:24439368; http://dx.doi.org/10.1016/j.cell.2013.12.012
   PubMed Web of Science ®Google Scholar
• Cheng Z, White MF. The AKTion in non-canonical insulin signaling. Nat Med 2012; 18:351-3; PMID:22395698; http://dx.doi.org/10.1038/nm.2694
   PubMed Web of Science ®Google Scholar
• Cheng Z, Tseng Y, White MF. Insulin signaling meets mitochondria in metabolism. Trend Endocrinol Metab: TEM 2010; 21:589-98; http://dx.doi.org/10.1016/j.tem.2010.06.005
   PubMed Web of Science ®Google Scholar
• Kim H, Hiraishi A, Tsuchiya K, Sakamoto K. (-) Epigallocatechin gallate suppresses the differentiation of 3T3-L1 preadipocytes through transcription factors FoxO1 and SREBP1c. Cytotechnology 2010; 62:245-55; PMID:20596890; http://dx.doi.org/10.1007/s10616-010-9285-x
   PubMed Web of Science ®Google Scholar
• Munekata K, Sakamoto K. Forkhead transcription factor Foxo1 is essential for adipocyte differentiation. In Vitro Cell Dev Biol An 2009; 45:642-51; http://dx.doi.org/10.1007/s11626-009-9230-5
   PubMed Web of Science ®Google Scholar
• Nakae J, Kitamura T, Kitamura Y, Biggs WH, 3rd, Arden KC, Accili D. The forkhead transcription factor Foxo1 regulates adipocyte differentiation. Dev Cell 2003; 4:119-29; PMID:12530968; http://dx.doi.org/10.1016/S1534-5807(02)00401-X
   PubMed Web of Science ®Google Scholar
• Dowell P, Otto TC, Adi S, Lane MD. Convergence of peroxisome proliferator-activated receptor gamma and Foxo1 signaling pathways. J Biol Chem 2003; 278:45485-91; PMID:12966085; http://dx.doi.org/10.1074/jbc.M309069200
   PubMed Web of Science ®Google Scholar
• Armoni M, Harel C, Karni S, Chen H, Bar-Yoseph F, Ver MR, Quon MJ, Karnieli E. FOXO1 represses peroxisome proliferator-activated receptor-gamma1 and -gamma2 gene promoters in primary adipocytes. A novel paradigm to increase insulin sensitivity. J Biol Chem 2006; 281:19881-91; PMID:16670091; http://dx.doi.org/10.1074/jbc.M600320200
   PubMed Web of Science ®Google Scholar
• Fan W, Imamura T, Sonoda N, Sears DD, Patsouris D, Kim JJ, Olefsky JM. FOXO1 transrepresses peroxisome proliferator-activated receptor gamma transactivation, coordinating an insulin-induced feed-forward response in adipocytes. J Biol Chem 2009; 284:12188-97; PMID:19246449; http://dx.doi.org/10.1074/jbc.M808915200
   PubMed Web of Science ®Google Scholar
• Kim JJ, Li P, Huntley J, Chang JP, Arden KC, Olefsky JM. FoxO1 haploinsufficiency protects against high-fat diet-induced insulin resistance with enhanced peroxisome proliferator-activated receptor gamma activation in adipose tissue. Diabetes 2009; 58:1275-82; PMID:19289458; http://dx.doi.org/10.2337/db08-1001
   PubMed Web of Science ®Google Scholar
• Cheng Z, Guo S, Copps K, Dong X, Kollipara R, Rodgers JT, Depinho RA, Puigserver P, White MF. Foxo1 integrates insulin signaling with mitochondrial function in the liver. Nat Med 2009; 15:1307-11; PMID:19838201; http://dx.doi.org/10.1038/nm.2049
   PubMed Web of Science ®Google Scholar
• Cheng Z, White MF. Foxo1 in hepatic lipid metabolism. Cell Cycle 2010; 9:219-20; PMID:20023377; http://dx.doi.org/10.4161/cc.9.2.10567
   PubMed Web of Science ®Google Scholar
• Dong XC, Copps KD, Guo S, Li Y, Kollipara R, DePinho RA, White MF. Inactivation of hepatic Foxo1 by insulin signaling is required for adaptive nutrient homeostasis and endocrine growth regulation. Cell Metab 2008; 8:65-76; PMID:18590693; http://dx.doi.org/10.1016/j.cmet.2008.06.006
   PubMed Web of Science ®Google Scholar
• Nagashima T, Shigematsu N, Maruki R, Urano Y, Tanaka H, Shimaya A, Shimokawa T, Shibasaki M. Discovery of novel forkhead box O1 inhibitors for treating type 2 diabetes: improvement of fasting glycemia in diabetic db/db mice. Mol Pharmacol 2010; 78:961-70; PMID:20736318; http://dx.doi.org/10.1124/mol.110.065714
   PubMed Web of Science ®Google Scholar
• Diep CH, Charles NJ, Gilks CB, Kalloger SE, Argenta PA, Lange CA. Progesterone receptors induce FOXO1-dependent senescence in ovarian cancer cells. Cell Cycle 2013; 12:1433-49; PMID:23574718; http://dx.doi.org/10.4161/cc.24550
   PubMed Web of Science ®Google Scholar
• Mortuza R, Chen S, Feng B, Sen S, Chakrabarti S. High glucose induced alteration of SIRTs in endothelial cells causes rapid aging in a p300 and FOXO regulated pathway. PloS one 2013; 8:e54514; PMID:23342163; http://dx.doi.org/10.1371/journal.pone.0054514
   PubMed Web of Science ®Google Scholar
• Zebisch K, Voigt V, Wabitsch M, Brandsch M. Protocol for effective differentiation of 3T3-L1 cells to adipocytes. Anal Biochem 2012; 425:88-90; PMID:22425542; http://dx.doi.org/10.1016/j.ab.2012.03.005
   PubMed Web of Science ®Google Scholar
• Spiegelman BM. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998; 47:507-14; PMID:9568680; http://dx.doi.org/10.2337/diabetes.47.4.507
   PubMed Web of Science ®Google Scholar
• Ramirez-Zacarias JL, Castro-Munozledo F, Kuri-Harcuch W. Quantitation of adipose conversion and triglycerides by staining intracytoplasmic lipids with Oil red O. Histochem 1992; 97:493-7; http://dx.doi.org/10.1007/BF00316069
   Google Scholar
• Guo S, Copps KD, Dong X, Park S, Cheng Z, Pocai A, Rossetti L, Sajan M, Farese RV, White MF. The Irs1 branch of the insulin signaling cascade plays a dominant role in hepatic nutrient homeostasis. Mol Cell Biol 2009; 29:5070-83; PMID:19596788; http://dx.doi.org/10.1128/MCB.00138-09
   PubMed Web of Science ®Google Scholar